Responding to a story published today in The Times, the Association of the British Pharmaceutical Industry (ABPI) have issued the following statement.
"The Times article today [22 September] does not give the full picture of the constructive initial meeting between the UK EU Steering Group and Government Ministers on September 6th regarding priorities for Life Sciences as the UK prepares to exit the European Union.
The report and presentation delivered to Ministers featured a range of options for Government to begin to consider across these areas, with an intention of having further discussions once any future relationship between Britain and Europe is more clearly defined.
We are delighted that Ministers recognised the crucial importance of the life sciences sector to UK PLC and are committed to working with us to ensure a flourishing sector in the future. The next meeting of the Steering Group and Government will take place in November 2016.
The report was published on Tuesday 20th September."
ABPI Press OfficeEmail: firstname.lastname@example.org to 5pm Monday to Friday: +44 (0) 20 7747 7147 or +44 (0) 20 7747 14415pm to 9am and weekends: +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
About the UK EU Life Sciences Steering Group
Former Life Sciences Minister, George Freeman, announced on 11 July 2016 that a UK EU Life Sciences Steering Group would be established to consider "how the UK can seize the opportunity to define a new relationship with the EU".
The ABPI and the BioIndustry Association (BIA) employed PricewaterhouseCoopers LLP (PwC) to produce a report and presentation ahead of the 6 September meeting with Ministers in order to comprehensively analyse the opportunities and challenges for Life Sciences in the UK as Britain negotiates a new relationship with the EU.
Workshops were held with 150 experts from industry, Non-Governmental Organisations (NGOs) and public sector organisations covering pharmaceuticals, biotech, medical technology, consumer health, animal health, support services.